Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-0523-L001 in Advanced Endocrine Tumors
NCT06141369Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of mRNA-0523-L001 in adrenocortical carcinoma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine carcinoma (TNEC) and 1 more, sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoints: Maximum tolerated dose (MTD) or Dose-limiting toxicity (DLT) at 3 weeks and Incidence of treatment-related adverse events at 3 weeks. Started Jan 2024; status: recruiting.
02
Drugs
mRNA-0523-L001
03
Conditions
adrenocortical carcinoma (ACC)medullary thyroid carcinoma (MTC)thymic neuroendocrine carcinoma (TNEC)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT06141369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141369.